Macquarie University is a public research university based in Sydney, Australia, in the suburb of Macquarie Park. Founded in 1964 by the New South Wales Government, it was the third university to be established in the metropolitan area of Sydney.

During the past decade, Macquarie University conducted 47 clinical trials. In the 10-year time frame, 47 clinical trials started and 8 clinical trials were completed, i.e. on average, 17% percent of trials that started reached the finish line to date. In the past 5 years, 34 clinical trials started and 6 clinical trials were completed. i.e. 17.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Macquarie University" #1 sponsor was "United Therapeutics" with 6 trials, followed by "Collaborative Medicinal Development Pty Limited" with 4 trials sponsored, "Pfizer" with 4 trials sponsored, "Boehringer Ingelheim" with 3 trials sponsored and "Macquarie University, Australia" with 3 trials sponsored. Other sponsors include 30 different institutions and companies that sponsored additional 37 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Macquarie University" #1 collaborator was "Macquarie University, Australia" with 5 trials as a collaborator, "Astellas Pharma Inc" with 3 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 3 trials as a collaborator, "Novotech (Australia) Pty Limited" with 3 trials as a collaborator and "FightMND" with 2 trials as a collaborator. Other collaborators include 55 different institutions and companies that were collaborators in the rest 65 trials.

According to Clinical.Site data, the most researched conditions in "Macquarie University" are "Prostate Cancer" (6 trials), "Pulmonary Arterial Hypertension" (5 trials), "Amyotrophic Lateral Sclerosis" (4 trials), "Cardiovascular Diseases" (3 trials) and "Familial Primary Pulmonary Hypertension" (3 trials). Many other conditions were trialed in "Macquarie University" in a lesser frequency.

Most popular intervention types in "Macquarie University" are "Drug" (46 trials), "Biological" (7 trials), "Device" (4 trials), "Other" (3 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "Enzalutamide" (7 trials), "Pembrolizumab" (6 trials), "Cu(II)ATSM" (4 trials) and "Prednisone" (3 trials). Other intervention names were less common.

The vast majority of trials in "Macquarie University" are 42 trials for "All" genders, 12 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Macquarie University". undefined are not yet recruiting, 22 are recruiting, 10 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 16 completed trials in Macquarie University, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Macquarie University, 16 "Phase 1" clinical trials were conducted, 24 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 3 trials that are defined as “Not Applicable".